Forecasting the Future of Cardiovascular Disease in the United States

Paul A. Heidenreich(American Heart Association), Justin G. Trogdon, Olga Khavjou(American Heart Association), Javed Butler(American Heart Association), Kathleen Dracup(American Heart Association), Michael D. Ezekowitz(American Heart Association), Eric Finkelstein(American Heart Association), Yuling Hong(American Heart Association), S. Claiborne Johnston(Neurology, Inc), Amit V. Khera, Donald M. Lloyd‐Jones(General Department of Preventive Medicine), Sue Nelson(American Heart Association), Graham Nichol(American Heart Association), Diane Orenstein(American Heart Association), Peter W.F. Wilson(American Heart Association), Y. Joseph Woo(American Heart Association)
Circulation
January 25, 2011
Cited by 3,229Open Access
Full Text

Abstract

BACKGROUND: Cardiovascular disease (CVD) is the leading cause of death in the United States and is responsible for 17% of national health expenditures. As the population ages, these costs are expected to increase substantially. METHODS AND RESULTS: To prepare for future cardiovascular care needs, the American Heart Association developed methodology to project future costs of care for hypertension, coronary heart disease, heart failure, stroke, and all other CVD from 2010 to 2030. This methodology avoided double counting of costs for patients with multiple cardiovascular conditions. By 2030, 40.5% of the US population is projected to have some form of CVD. Between 2010 and 2030, real (2008$) total direct medical costs of CVD are projected to triple, from $273 billion to $818 billion. Real indirect costs (due to lost productivity) for all CVD are estimated to increase from $172 billion in 2010 to $276 billion in 2030, an increase of 61%. CONCLUSIONS: These findings indicate CVD prevalence and costs are projected to increase substantially. Effective prevention strategies are needed if we are to limit the growing burden of CVD.


Related Papers

No related papers found

Powered by citation graph analysis